001     142037
005     20240229105140.0
024 7 _ |2 doi
|a 10.1001/jamaoncol.2018.2706
024 7 _ |2 pmid
|a pmid:29860482
024 7 _ |2 pmc
|a pmc:PMC6248091
024 7 _ |2 ISSN
|a 2374-2437
024 7 _ |2 ISSN
|a 2374-2445
024 7 _ |a altmetric:43183335
|2 altmetric
037 _ _ |a DKFZ-2018-02267
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Global Burden of Disease Cancer Collaboration
|b 0
|e Collaboration Author
245 _ _ |a Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study.
260 _ _ |a Chicago, Ill.
|b American Medical Association
|c 2018
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1549885966_1500
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a The increasing burden due to cancer and other noncommunicable diseases poses a threat to human development, which has resulted in global political commitments reflected in the Sustainable Development Goals as well as the World Health Organization (WHO) Global Action Plan on Non-Communicable Diseases. To determine if these commitments have resulted in improved cancer control, quantitative assessments of the cancer burden are required.To assess the burden for 29 cancer groups over time to provide a framework for policy discussion, resource allocation, and research focus.Cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) were evaluated for 195 countries and territories by age and sex using the Global Burden of Disease study estimation methods. Levels and trends were analyzed over time, as well as by the Sociodemographic Index (SDI). Changes in incident cases were categorized by changes due to epidemiological vs demographic transition.In 2016, there were 17.2 million cancer cases worldwide and 8.9 million deaths. Cancer cases increased by 28% between 2006 and 2016. The smallest increase was seen in high SDI countries. Globally, population aging contributed 17%; population growth, 12%; and changes in age-specific rates, -1% to this change. The most common incident cancer globally for men was prostate cancer (1.4 million cases). The leading cause of cancer deaths and DALYs was tracheal, bronchus, and lung cancer (1.2 million deaths and 25.4 million DALYs). For women, the most common incident cancer and the leading cause of cancer deaths and DALYs was breast cancer (1.7 million incident cases, 535 000 deaths, and 14.9 million DALYs). In 2016, cancer caused 213.2 million DALYs globally for both sexes combined. Between 2006 and 2016, the average annual age-standardized incidence rates for all cancers combined increased in 130 of 195 countries or territories, and the average annual age-standardized death rates decreased within that timeframe in 143 of 195 countries or territories.Large disparities exist between countries in cancer incidence, deaths, and associated disability. Scaling up cancer prevention and ensuring universal access to cancer care are required for health equity and to fulfill the global commitments for noncommunicable disease and cancer control.
536 _ _ |0 G:(DE-HGF)POF3-313
|a 313 - Cancer risk factors and prevention (POF3-313)
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Fitzmaurice, Christina
|b 1
700 1 _ |a Akinyemiju, Tomi F
|b 2
700 1 _ |a Al Lami, Faris Hasan
|b 3
700 1 _ |a Alam, Tahiya
|b 4
700 1 _ |a Alizadeh-Navaei, Reza
|b 5
700 1 _ |a Allen, Christine
|b 6
700 1 _ |a Alsharif, Ubai
|b 7
700 1 _ |a Alvis-Guzman, Nelson
|b 8
700 1 _ |a Amini, Erfan
|b 9
700 1 _ |a Anderson, Benjamin O
|b 10
700 1 _ |a Aremu, Olatunde
|b 11
700 1 _ |a Artaman, Al
|b 12
700 1 _ |a Asgedom, Solomon Weldegebreal
|b 13
700 1 _ |a Assadi, Reza
|b 14
700 1 _ |a Atey, Tesfay Mehari
|b 15
700 1 _ |a Avila-Burgos, Leticia
|b 16
700 1 _ |a Awasthi, Ashish
|b 17
700 1 _ |a Ba Saleem, Huda Omer
|b 18
700 1 _ |a Barac, Aleksandra
|b 19
700 1 _ |a Bennett, James R
|b 20
700 1 _ |a Bensenor, Isabela M
|b 21
700 1 _ |a Bhakta, Nickhill
|b 22
700 1 _ |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|a Brenner, Hermann
|b 23
|u dkfz
700 1 _ |a Cahuana-Hurtado, Lucero
|b 24
700 1 _ |a Castañeda-Orjuela, Carlos A
|b 25
700 1 _ |a Catalá-López, Ferrán
|b 26
700 1 _ |a Choi, Jee-Young Jasmine
|b 27
700 1 _ |a Christopher, Devasahayam Jesudas
|b 28
700 1 _ |a Chung, Sheng-Chia
|b 29
700 1 _ |a Curado, Maria Paula
|b 30
700 1 _ |a Dandona, Lalit
|b 31
700 1 _ |a Dandona, Rakhi
|b 32
700 1 _ |a das Neves, José
|b 33
700 1 _ |a Dey, Subhojit
|b 34
700 1 _ |a Dharmaratne, Samath D
|b 35
700 1 _ |a Doku, David Teye
|b 36
700 1 _ |a Driscoll, Tim R
|b 37
700 1 _ |a Dubey, Manisha
|b 38
700 1 _ |a Ebrahimi, Hedyeh
|b 39
700 1 _ |a Edessa, Dumessa
|b 40
700 1 _ |a El-Khatib, Ziad
|b 41
700 1 _ |a Endries, Aman Yesuf
|b 42
700 1 _ |a Fischer, Florian
|b 43
700 1 _ |a Force, Lisa M
|b 44
700 1 _ |a Foreman, Kyle J
|b 45
700 1 _ |a Gebrehiwot, Solomon Weldemariam
|b 46
700 1 _ |a Gopalani, Sameer Vali
|b 47
700 1 _ |a Grosso, Giuseppe
|b 48
700 1 _ |a Gupta, Rahul
|b 49
700 1 _ |a Gyawali, Bishal
|b 50
700 1 _ |a Hamadeh, Randah Ribhi
|b 51
700 1 _ |a Hamidi, Samer
|b 52
700 1 _ |a Harvey, James
|b 53
700 1 _ |a Hassen, Hamid Yimam
|b 54
700 1 _ |a Hay, Roderick J
|b 55
700 1 _ |a Hay, Simon I
|b 56
700 1 _ |a Heibati, Behzad
|b 57
700 1 _ |a Hiluf, Molla Kahssay
|b 58
700 1 _ |a Horita, Nobuyuki
|b 59
700 1 _ |a Hosgood, H Dean
|b 60
700 1 _ |a Ilesanmi, Olayinka S
|b 61
700 1 _ |a Innos, Kaire
|b 62
700 1 _ |a Islami, Farhad
|b 63
700 1 _ |a Jakovljevic, Mihajlo B
|b 64
700 1 _ |a Johnson, Sarah Charlotte
|b 65
700 1 _ |a Jonas, Jost B
|b 66
700 1 _ |a Kasaeian, Amir
|b 67
700 1 _ |a Kassa, Tesfaye Dessale
|b 68
700 1 _ |a Khader, Yousef Saleh
|b 69
700 1 _ |a Khan, Ejaz Ahmad
|b 70
700 1 _ |a Khan, Gulfaraz
|b 71
700 1 _ |a Khang, Young-Ho
|b 72
700 1 _ |a Khosravi, Mohammad Hossein
|b 73
700 1 _ |a Khubchandani, Jagdish
|b 74
700 1 _ |a Kopec, Jacek A
|b 75
700 1 _ |a Kumar, G Anil
|b 76
700 1 _ |a Kutz, Michael
|b 77
700 1 _ |a Lad, Deepesh Pravinkumar
|b 78
700 1 _ |a Lafranconi, Alessandra
|b 79
700 1 _ |a Lan, Qing
|b 80
700 1 _ |a Legesse, Yirga
|b 81
700 1 _ |a Leigh, James
|b 82
700 1 _ |a Linn, Shai
|b 83
700 1 _ |a Lunevicius, Raimundas
|b 84
700 1 _ |a Majeed, Azeem
|b 85
700 1 _ |a Malekzadeh, Reza
|b 86
700 1 _ |a Malta, Deborah Carvalho
|b 87
700 1 _ |a Mantovani, Lorenzo G
|b 88
700 1 _ |a McMahon, Brian J
|b 89
700 1 _ |a Meier, Toni
|b 90
700 1 _ |a Melaku, Yohannes Adama
|b 91
700 1 _ |a Melku, Mulugeta
|b 92
700 1 _ |a Memiah, Peter
|b 93
700 1 _ |a Mendoza, Walter
|b 94
700 1 _ |a Meretoja, Tuomo J
|b 95
700 1 _ |a Mezgebe, Haftay Berhane
|b 96
700 1 _ |a Miller, Ted R
|b 97
700 1 _ |a Mohammed, Shafiu
|b 98
700 1 _ |a Mokdad, Ali H
|b 99
700 1 _ |a Moosazadeh, Mahmood
|b 100
700 1 _ |a Moraga, Paula
|b 101
700 1 _ |a Mousavi, Seyyed Meysam
|b 102
700 1 _ |a Nangia, Vinay
|b 103
700 1 _ |a Nguyen, Cuong Tat
|b 104
700 1 _ |a Nong, Vuong Minh
|b 105
700 1 _ |a Ogbo, Felix Akpojene
|b 106
700 1 _ |a Olagunju, Andrew Toyin
|b 107
700 1 _ |a Pa, Mahesh
|b 108
700 1 _ |a Park, Eun-Kee
|b 109
700 1 _ |a Patel, Tejas
|b 110
700 1 _ |a Pereira, David M
|b 111
700 1 _ |a Pishgar, Farhad
|b 112
700 1 _ |a Postma, Maarten J
|b 113
700 1 _ |a Pourmalek, Farshad
|b 114
700 1 _ |a Qorbani, Mostafa
|b 115
700 1 _ |a Rafay, Anwar
|b 116
700 1 _ |a Rawaf, Salman
|b 117
700 1 _ |a Rawaf, David Laith
|b 118
700 1 _ |a Roshandel, Gholamreza
|b 119
700 1 _ |a Safiri, Saeid
|b 120
700 1 _ |a Salimzadeh, Hamideh
|b 121
700 1 _ |a Sanabria, Juan Ramon
|b 122
700 1 _ |a Santric Milicevic, Milena M
|b 123
700 1 _ |a Sartorius, Benn
|b 124
700 1 _ |a Satpathy, Maheswar
|b 125
700 1 _ |a Sepanlou, Sadaf G
|b 126
700 1 _ |a Shackelford, Katya Anne
|b 127
700 1 _ |a Shaikh, Masood Ali
|b 128
700 1 _ |a Sharif-Alhoseini, Mahdi
|b 129
700 1 _ |a She, Jun
|b 130
700 1 _ |a Shin, Min-Jeong
|b 131
700 1 _ |a Shiue, Ivy
|b 132
700 1 _ |a Shrime, Mark G
|b 133
700 1 _ |a Sinke, Abiy Hiruye
|b 134
700 1 _ |a Sisay, Mekonnen
|b 135
700 1 _ |a Sligar, Amber
|b 136
700 1 _ |a Sufiyan, Muawiyyah Babale
|b 137
700 1 _ |a Sykes, Bryan L
|b 138
700 1 _ |a Tabarés-Seisdedos, Rafael
|b 139
700 1 _ |a Tessema, Gizachew Assefa
|b 140
700 1 _ |a Topor-Madry, Roman
|b 141
700 1 _ |a Tran, Tung Thanh
|b 142
700 1 _ |a Tran, Bach Xuan
|b 143
700 1 _ |a Ukwaja, Kingsley Nnanna
|b 144
700 1 _ |a Vlassov, Vasiliy Victorovich
|b 145
700 1 _ |a Vollset, Stein Emil
|b 146
700 1 _ |a Weiderpass, Elisabete
|b 147
700 1 _ |a Williams, Hywel C
|b 148
700 1 _ |a Yimer, Nigus Bililign
|b 149
700 1 _ |a Yonemoto, Naohiro
|b 150
700 1 _ |a Younis, Mustafa Z
|b 151
700 1 _ |a Murray, Christopher J L
|b 152
700 1 _ |a Naghavi, Mohsen
|b 153
773 _ _ |0 PERI:(DE-600)2810928-4
|a 10.1001/jamaoncol.2018.2706
|g Vol. 4, no. 11, p. 1553 -
|n 11
|p 1553-1568
|t JAMA oncology
|v 4
|x 2374-2437
|y 2018
909 C O |o oai:inrepo02.dkfz.de:142037
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|a Deutsches Krebsforschungszentrum
|b 23
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF3-313
|1 G:(DE-HGF)POF3-310
|2 G:(DE-HGF)POF3-300
|a DE-HGF
|l Krebsforschung
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b JAMA ONCOL : 2017
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)1110
|2 StatID
|a DBCoverage
|b Current Contents - Clinical Medicine
915 _ _ |0 StatID:(DE-HGF)9920
|2 StatID
|a IF >= 20
|b JAMA ONCOL : 2017
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l Klinische Epidemiologie und Alternsforschung
|x 0
920 1 _ |0 I:(DE-He78)G110-20160331
|k G110
|l Präventive Onkologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)G110-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21